ENLIVEN THERAPEUTICS INC (ELVN)

Company Profile

Enliven Therapeutics, Inc. operates as a a clinical stage precision oncology company. The company is headquartered in Boulder, Colorado and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm focuses on addressing existing and emerging unmet needs with a precision oncology approach. The firm is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC).

Company Info

ENLIVEN THERAPEUTICS INC

6200 Lookout Road

Boulder COLORADO

P: 17206478519

Employees: 6

Website: https://www.enliventherapeutics.com/